Item Details

abstract

BACKGROUND: About 1 in 8 men will be diagnosed with prostate cancer in their lifetime. Out of these men, 80% of advanced prostate cancer cases will develop metastases to the bone. There is currently no treatment for metastatic prostate cancer, only palliative treatment. Patients with bone metastases experience skeletal fractures, spinal cord compression, decreased mobility, and bone pain. Prior to metastasis, communication between the tumor and bone environment exists. Prostate cancer promotes osteoblastic activity causing bone formation to occur. CD117 and SCF have been shown to correlate with advanced prostate cancer, where the highest expression seen in the metastatic lesion. SCF has also been shown to increase in patients’ platelet releasates as prostate cancer progresses. SCF is expressed by both megakaryocytes, which produce platelets, and osteoblasts, which cause bone formation. Platelets and osteoblasts have been implicated in prostate cancer metastasis and the tumor to bone communication prior to metastatic lesion formation

subject

Bone Metastasis

Cancer Metastasis

CD117

Prostate Cancer

SCF

contributor

Foster, Brittni Meghan (author)

Kerr, Bethany (committee chair)

Almeida-Porada, Graca (committee member)

Shiozawa, Yusuke (committee member)

Bitting, Rhonda (committee member)

Peters, Chris (committee member)

date

2022-01-15T09:35:25Z (accessioned)

2022-07-14T08:30:13Z (available)

2021 (issued)

degree

Molecular Medicine and Translational Science (discipline)

embargo

2022-07-14 (terms)

identifier

http://hdl.handle.net/10339/99378 (uri)

language

en (iso)

publisher

Wake Forest University

title

THE CHARACTERIZATION OF BONE MARROW-DERIVED STEM CELL FACTOR AND ITS ROLE IN PROSTATE CANCER METASTASIS

type

Dissertation